NBIX Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$115.71 |
| 52 Week High | US$157.98 |
| 52 Week Low | US$84.23 |
| Beta | 0.26 |
| 1 Month Change | 21.44% |
| 3 Month Change | -5.64% |
| 1 Year Change | -15.35% |
| 3 Year Change | 37.55% |
| 5 Year Change | -0.68% |
| Change since IPO | 825.68% |
Recent News & Updates
Recent updates
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 07
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Apr 22Do Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Warrant Your Attention?
Apr 18Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity
Apr 16
Neurocrine Biosciences revenue will grow by 10% with Crenessity and Ingrezza sales if they can maintain the retail price.
Mar 20Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors
Mar 05Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
Feb 21Neurocrine Biosciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Feb 08Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Dec 18Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price
Dec 09Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
Oct 10The Play On Neurocrine Biosciences
Oct 02Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Aug 28
Increasing Market Penetration And Product Diversification Fuel Revenue Growth And Future Potential
Aug 21 Expansion into new treatment areas and product portfolio diversification signal potential for increased revenue and market presence.Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Shareholder Returns
| NBIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.5% | -9.0% | -0.3% |
| 1Y | -15.4% | -15.2% | 8.0% |
Return vs Industry: NBIX matched the US Biotechs industry which returned -15.2% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 8% over the past year.
Price Volatility
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NBIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NBIX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,800 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
Neurocrine Biosciences, Inc. Fundamentals Summary
| NBIX fundamental statistics | |
|---|---|
| Market cap | US$11.63b |
| Earnings (TTM) | US$305.80m |
| Revenue (TTM) | US$2.41b |
37.4x
P/E Ratio4.7x
P/S RatioIs NBIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBIX income statement (TTM) | |
|---|---|
| Revenue | US$2.41b |
| Cost of Revenue | US$870.60m |
| Gross Profit | US$1.54b |
| Other Expenses | US$1.24b |
| Earnings | US$305.80m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.09 |
| Gross Margin | 63.91% |
| Net Profit Margin | 12.68% |
| Debt/Equity Ratio | 0% |
How did NBIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 12:50 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurocrine Biosciences, Inc. is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |